Table 3 System Organ Classes (SOCs) for the five most frequently reported grade 3 or 4 Adverse Events (AEs) reported by HIV-positive and HIV-negative patients in the matched population during enrolment in the REMoxTB trial. Total number of grade 3 or 4 adverse events of the SOC shown according to HIV status and percentage of total number of grade 3 or 4 AEs in HIV group provided in brackets
Adverse Event SOC | HIV-positive Patients (% of G3+ Events) | HIV-negative Patients (% of G3+ Events) |
|---|---|---|
Hepatobiliary disorders | 12 (30.0%) | 15 (25.0%) |
Respiratory and thoracic disorders | 7 (17.5%) | 13 (21.7%) |
Blood and lymphatic disorders | 6 (15.0%) | 10 (16.7%) |
Infections and infestations | 3 (7.5%) | 5 (8.3%) |
Metabolism and nutrition disorders | 3 (7.5%) | 4 (6.7%) |
Other | 9 (17.5%) | 13 (16.7%) |